Diploma (LON:DPLM) Stock Price Up 15.1% - Still a Buy?

Diploma PLC (LON:DPLM - Get Free Report) rose 15.1% during mid-day trading on Wednesday . The company traded as high as GBX 5,025 ($67.30) and last traded at GBX 4,860 ($65.09). Approximately 975,747 shares were traded during mid-day trading, an increase of 115% from the average daily volume of 453,933 shares. The stock had previously closed at GBX 4,222 ($56.54).

Diploma Trading Up 0.0%

The stock has a market capitalization of £6.49 billion, a price-to-earnings ratio of 55.89, a PEG ratio of 2.82 and a beta of 0.75. The company has a debt-to-equity ratio of 62.17, a quick ratio of 0.80 and a current ratio of 2.17. The business has a 50-day moving average of GBX 3,949.28 and a 200-day moving average of GBX 4,253.28.

Diploma (LON:DPLM - Get Free Report) last announced its earnings results on Wednesday, May 21st. The company reported GBX 80.20 ($1.07) earnings per share (EPS) for the quarter. Diploma had a return on equity of 13.18% and a net margin of 9.25%. As a group, research analysts forecast that Diploma PLC will post 163.7995512 EPS for the current year.

Insider Buying and Selling at Diploma

In related news, insider Ian El-Mokadem bought 500 shares of the stock in a transaction on Monday, March 24th. The shares were bought at an average cost of GBX 3,948 ($52.87) per share, for a total transaction of £19,740 ($26,436.32). Also, insider David S. Lowden bought 750 shares of the stock in a transaction on Friday, March 21st. The stock was bought at an average price of GBX 3,928 ($52.60) per share, for a total transaction of £29,460 ($39,453.60). Company insiders own 0.52% of the company's stock.

Diploma Company Profile

Diploma PLC, together with its subsidiaries, supplies specialized technical products and services in the United Kingdom, Continental Europe, North America, and internationally. It operates through three business sectors: Life Sciences, Seals, and Controls. The Life Sciences sector supplies technology-enabled products used in surgical procedures in operating theatres and endoscopy; testing equipment and services for clinical laboratories; and bio-pharma, food safety and testing, and other research-oriented products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.